Navigation Links
Favrille Reports First Quarter 2008 Financial Results
Date:5/8/2008

irst quarter of 2007.

Marketing, general and administrative expense was approximately $2.6 million for the first quarter of 2008, compared to approximately $2.9 million during the same period in 2007. The decrease is primarily due to a decrease in cash bonus expense, stock-based compensation and travel expenses. Total stock-based compensation included in marketing, general and administrative expense was approximately $560,000 for the quarter, compared to approximately $660,000 for the first quarter of 2007.

As of March 31, 2008, Favrille had cash, cash equivalents and short-term investments of $19.7 million, compared to $29.9 million at December 31, 2007. The decrease is primarily due to net cash used to fund ongoing operations. Loan and security agreements with Favrille's senior lenders require the Company to maintain a minimum of $15 million in available cash, cash equivalents and short-term investments. In the event Favrille's available cash should fall below the minimum requirement, the lenders could require a letter of credit equal to the outstanding loan balances at that time, in which case the Company would be required to use a significant amount of its available cash for collateral.

"For the past eight years we have worked diligently to fund the company, from inception up to and including our Phase 3 registration trial, while making every effort to maximize shareholder value," said Tamara A. Seymour, Chief Financial Officer of Favrille. "We expect that our cash on hand is sufficient to fund operations through our Phase 3 data analysis this quarter, after which we will explore our financing options."

Phase 3 Registration Trial Update

Favrille reached the data cutoff date for its Phase 3 registration trial of Specifid following Rituxan(R) in patients with follicular B-cell non-Hodgkin's lymphoma (NHL) in April 2008. As of the data cutoff date, 205 of the 349 patients randomized have experienced disease progression (relapsed)
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Favrille to Host Conference Call and Live Webcast to Discuss First Quarter 2008 Financial Results on May 8, 2008
2. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
3. Favrille Announces $21.1 Million Registered Direct Offering
4. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
5. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
6. Favrille to Present at BIO InvestorForum
7. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
8. Favrille CEO to Present at Bear Stearns Healthcare Conference
9. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
10. Barr Reports First Quarter 2008 GAAP Earnings of $0.21 Per Share; Adjusted Earnings of $0.57 Per Share
11. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Md. , Sept. 16, 2014   ... biotechnology company developing novel anti-infective biologic and drug ... and diseases, announced today the completion of the Company,s ... which highlighted its irritable bowel syndrome (IBS) ... constipation-predominant IBS (C-IBS). In the keynote ...
(Date:9/16/2014)... , Sept. 16, 2014  Ascendis Pharma ... TransCon technology to address significant unmet medical needs, ... Phase 2 pediatric study to evaluate once-weekly TransCon ... or GHD.  The full interim results will be ... GRS and IGF Society, being held October 15-18, ...
(Date:9/15/2014)... NYHeat drives classical phase transitionsthink solid, liquid, ... when the temperature drops. If phase transitions ... quantum mechanics reigns, subtle fluctuations can dramatically ... the U.S. Department of Energy,s Brookhaven National ... this frigid landscape of absolute zero to ...
(Date:9/15/2014)... University have developed a technique for controlling the surface ... opening the door to a new generation of reconfigurable ... on the fact that the oxide "skin" of the ... acts as a surfactant, lowering the surface tension between ... used a liquid metal alloy of gallium and indium. ...
Breaking Biology Technology:Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Elusive quantum transformations found near absolute zero 2Elusive quantum transformations found near absolute zero 3Researchers control surface tension to manipulate liquid metals 2
... MINRAD,International, Inc. (Amex: BUF ) today announced that ... aggregate of $40.0 million of senior,secured convertible notes with ... The notes pay an 8% coupon, have a 3 ... The aggregate net,proceeds of the notes, after deducting the ...
... Biotech and pharma companies,are increasingly utilizing novel ... early in the development cycle to avoid ... and,Biotechnology News (GEN) ( http://www.genengnews.com/ ). By ... early, pharma also has the opportunity to ...
... Scientific,Corporation (NYSE: BSX ) announced today that ... issued its ruling in an,arbitration between the Company ... pursuant to the 2005 settlement agreement between,the companies, ... various U.S. and European patents held by Medinol. ...
Cached Biology Technology:MINRAD International, Inc. Announces $40.0 Million Private Placement 2MINRAD International, Inc. Announces $40.0 Million Private Placement 3Genetic Engineering and Biotechnology News (GEN) Reports on Early ADMET Use 2WIPO Panel Rules Boston Scientific Liberte(R) and TAXUS(R) Liberte(R) Stents Do Not Infringe Medinol Patents 2WIPO Panel Rules Boston Scientific Liberte(R) and TAXUS(R) Liberte(R) Stents Do Not Infringe Medinol Patents 3
(Date:9/16/2014)... interaction between viruses, bacteria, and their environment is ... collaboration between Matthew Sullivan, associate professor in the ... Biology and Steven Hallam from the University of ... are drivers of nutrient and energy cycles that ... is changing, so are the environments these bacteria ...
(Date:9/16/2014)... Schizophrenia is associated with increased rates and intensity of ... that the relationship between schizophrenia and smoking stems, in ... to self-medicate symptoms and cognitive impairment associated with the ... issue of Biological Psychiatry , sheds light on ... nicotine receptors in the brain was lower in schizophrenia ...
(Date:9/16/2014)... Proteins are responsible for practically all vital functions ... reactions, forward signals, transport particular substances and control ... that proteins do not function independently of each ... you examine the protein networks, you find many ... Falter-Braun from TUM,s Chair of Plant Systems Biology. ...
Breaking Biology News(10 mins):New research decodes virus-host interactions in ocean dead zones 2New research decodes virus-host interactions in ocean dead zones 3Smoking and schizophrenia linked by alterations in brain nicotine signals 2Good networkers make prime targets 2
... The Society of Interventional Radiology Foundation,s Discovery Campaign, ... invasive medicine into new areas of discovery, announced ... a manufacturer of medical devices, pharmaceuticals and medical ... and is a "Visionary" level supporter. ...
... In the waters off the North Carolina coast, historically-significant ... seafloor, a testament to a relatively unknown chapter in ... shipwrecks are not only important for their cultural value, ... fishes, invertebrates and algal species. Additionally, due to their ...
... by two teams of Army scientists and collaborators has identified ... virus infection. The findings, published online today in separate studies ... for combating one of the world,s most deadly viruses. ... high as 90 percent in humans. The virus is of ...
Cached Biology News:Single protein, key to ebola virus infection, could aid in drug design 2
... Cloning Kits are designed to speed up the ... PCR products, regardless of sequence or type of ... including those that are difficult to clone by ... unstable or code for potentially detrimental proteins can ...
... Blunt-Ended PCR Cloning Kit, 40 reactions. ... cloning of all PCR products with ... cloning approaches by offering consistently better ... 25-fold more positive clones.Amplicons generated by ...
Antibodies were affinity purified using epitopes specific to XLF immobilized on solid support....
... Clone/PAD: ZMD.460. Immunogen: Synthetic peptide ... human C35 protein (chromosome 17 open reading ... Specific for the C35 protein. On ... at ~15 kDa band. Reactivity: Human ...
Biology Products: